Therapeutic agent for meibomian dysfunction
AssigneeSanten Pharmaceutical Co., Ltd.
InventorsHideki MIYAKE, Tomoko ODA, Daisuke SHII
Life of this patent
Estimating the term…
Abstract
A method for treatment of meibomian gland dysfunction in a mammalian subject, the method involving administering to the mammalian subject an eye drop comprising 0.01 to 0.5% (w/v) of sirolimus or a pharmaceutically acceptable salt thereof as a sole active ingredient, wherein the eye drop is administered to the eyes of the mammalian subject 1 to 2 times per day.
Claims7
A method for treatment of meibomian gland dysfunction in a mammalian subject, the method comprising administering to the mammalian subject an eye drop comprising 0.01 to 0.5% (w/v) of sirolimus or a pharmaceutically acceptable salt thereof as a sole active ingredient, wherein the eye drop is administered to the eyes of the mammalian subject 1 to 2 times per day.
Dependencies are inferred from the claim text.